PMID- 30502662
OWN - NLM
STAT- MEDLINE
DCOM- 20190805
LR  - 20221207
IS  - 2212-1102 (Electronic)
IS  - 2212-1099 (Linking)
VI  - 18
DP  - 2019 May
TI  - Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in 
      Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in 
      India.
PG  - 65-73
LID - S2212-1099(18)30111-0 [pii]
LID - 10.1016/j.vhri.2018.06.002 [doi]
AB  - OBJECTIVES: To simulate the long-term health outcomes of canagliflozin 100 mg 
      versus glimepiride over 20 years in patients with type 2 diabetes mellitus (T2DM) 
      inadequately controlled on metformin from the perspective of the Indian health 
      care system. METHODS: Health outcomes were simulated using the validated Economic 
      and Health Outcomes Model of T2DM. Patient demographic characteristics, biomarker 
      values, and treatment effects were sourced from a subgroup of Indian patients 
      enrolled in a 52-week, head-to-head study of canagliflozin versus glimepiride 
      (mean maximum dose of 5.6 mg/d) in patients with T2DM inadequately controlled 
      with metformin. Outcomes were discounted at 5%. Sensitivity analyses were 
      conducted using alternative values for key model inputs. RESULTS: Relative to 
      glimepiride, treatment with canagliflozin 100 mg was associated with 
      approximately 14 more patients surviving at year 20 per 1,000 patients treated 
      and 0.43 quality-adjusted life-years gained, largely because of improved body 
      weight and reduced risk of macrovascular and microvascular morbidity over 20 
      years. Risk reductions were the largest for microvascular complications (e.g., 
      chronic kidney disease and albuminuria). Improved health outcomes were driven by 
      better glycated hemoglobin control associated with canagliflozin versus 
      glimepiride, which also delayed the need for rescue therapy. Key components of 
      quality-adjusted life-year gains included the avoidance of hypoglycemic episodes, 
      chronic kidney disease, and weight gain, as well as increased survival with 
      canagliflozin compared with glimepiride. CONCLUSIONS: Simulation results suggest 
      that canagliflozin 100 mg may provide better long-term health outcomes compared 
      with glimepiride in Indian patients with T2DM inadequately controlled with 
      metformin.
CI  - Copyright (c) 2018 ISPOR--The professional society for health economics and 
      outcomes research. Published by Elsevier Inc. All rights reserved.
FAU - Gupta, Vishal
AU  - Gupta V
AD  - "VG-ADVANTAGE" Diabetes, Thyroid and Endocrine Center and Breach Candy Hospital, 
      Mumbai, Maharashtra, India.
FAU - Willis, Michael
AU  - Willis M
AD  - The Swedish Institute for Health Economics, Lund, Sweden.
FAU - Johansen, Pierre
AU  - Johansen P
AD  - The Swedish Institute for Health Economics, Lund, Sweden.
FAU - Nilsson, Andreas
AU  - Nilsson A
AD  - The Swedish Institute for Health Economics, Lund, Sweden.
FAU - Shah, Manan
AU  - Shah M
AD  - Janssen India Medical Affairs, Mumbai, Maharashtra, India.
FAU - Mane, Amey
AU  - Mane A
AD  - Janssen India Medical Affairs, Mumbai, Maharashtra, India.
FAU - Neslusan, Cheryl
AU  - Neslusan C
AD  - Janssen Global Services, LLC, Raritan, NJ, USA. Electronic address: 
      cneslusa@its.jnj.com.
LA  - eng
PT  - Journal Article
DEP - 20181128
PL  - United States
TA  - Value Health Reg Issues
JT  - Value in health regional issues
JID - 101592642
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 9100L32L2N (Metformin)
MH  - Canagliflozin/*standards/therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/standards/therapeutic use
MH  - India
MH  - Metformin/standards/therapeutic use
MH  - Sodium-Glucose Transporter 2 Inhibitors/standards/therapeutic use
MH  - Sulfonylurea Compounds/*standards/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - SGLT2 inhibitors
OT  - health outcomes
OT  - modeling
OT  - type 2 diabetes
EDAT- 2018/12/07 06:00
MHDA- 2019/08/06 06:00
CRDT- 2018/12/04 06:00
PHST- 2017/10/12 00:00 [received]
PHST- 2018/04/11 00:00 [revised]
PHST- 2018/06/18 00:00 [accepted]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2019/08/06 06:00 [medline]
PHST- 2018/12/04 06:00 [entrez]
AID - S2212-1099(18)30111-0 [pii]
AID - 10.1016/j.vhri.2018.06.002 [doi]
PST - ppublish
SO  - Value Health Reg Issues. 2019 May;18:65-73. doi: 10.1016/j.vhri.2018.06.002. Epub 
      2018 Nov 28.